The aetiology of erectile dysfunction (ED) is multifactorial consisting of psychogenic and organic factors that must be considered in a multidisciplinary manner in order to treat effectively the disorder. New central initiators of erection such as apomorphine SL (Ixense TM ) provide a pharmacologically multidimensional approach to the treatment of ED. When used in conjunction with a psychosexual counselling strategy designed to move patients at high risk of failure to high responder groups, it can provide an effective and safe pharmacological therapy for ED.
Introduction
Erectile dysfunction (ED) has a multifactorial aetiology with psychogenic and organic factors playing an important role for many patients. The multifactorial nature of the disorder requires treatment strategies that address each factor and could include psychological and pharmacological approaches. This paper presents the concept that a dual approach utilising psychosexual counselling in conjunction with appropriate pharmacotherapy with the multidimensional drug, apomorphine SL (Ixense TM ) (apo SL), is an effective way to treat all patients, including those patients who would otherwise be at high risk of failure on pharmacotherapy alone.
Multidimensional nature of apo SL therapy
Apo SL has a novel, central mechanism of action at D 2 receptors in the hypothalamus, particularly the paraventricular nucleus (PVN).
1 Stimulation of D 2 receptors activates mainly oxytocinergic neural signaling, which in turn stimulates sacral spinal centres ( Figure 1 ) resulting in increased parasympathetic outflow and the activation of relaxation factors in the periphery leading to erection. 1 Activation of the PVN via apo SL requires appropriate sexual stimuli from higher cortical regions as the PVN acts as an integration centre for sexual responses, 2 this ensures that physiological erections are produced. 1 The physiological nature of erections produced with apo SL is further enhanced by the speed of action of the pharmacotherapy, for example, the time to reaction is 17-20 min for 2-and 3-mg doses of apo SL. 3, 4 The production of physiological erections is an advantage for an ED drug but an important consideration is the efficacy with which it produces this response. Studies have demonstrated that apo SL (2 and 3 mg) improves all clinical end points, including providing erections firm enough for intercourse, the percentage of attempts resulting in intercourse, intercourse satisfaction and orgasmic function. 1, 2 Thus, apo SL is efficacious as an ED therapy while also providing a good safety and tolerability profile. 1 The most common adverse events reported in clinical studies with 2-and 3-mg doses were headache (6.5%), nausea (4.5%) and dizziness (4.4%). 5 
Treating individuals
Target patients for a multidimensional drug such as apo SL are those patients in a stable relationship, with residual erectile function and mild-to-moderate ED. However, some of these patients will require additional strategies in order to move them to a high responder state rather than remaining as nonresponders or partial responders.
It is important to consider what makes a patient a poor responder. Some patients will have pathophysiological problems over and above the therapeutic possibilities of the drug prescribed, in which case alternate prescriptions or penile implants can be considered. In other patients, noncompliance or an unwillingness to continue treatment could impact on efficacy. It is vitally important that the correct method of administering the therapy is fully explained to the patient in order to avoid failure at an early stage of therapy and thus prevent further noncompliance. 6 Moreover, patients using apo SL should persist with the therapy for at least four to six attempts, as clinical studies have demonstrated that sequential administration improves efficacy particularly when accompanied by analytical discussions with the patient regarding the previous attempts and reiteration of the method of administering the drug. 6 However, multidisciplinary approaches to the treatment of this highly multifactorial disorder must also be considered. Psychosexual counselling can be applied in conjunction with pharmacological therapies in order to move the patient to a high responder state and enhance the efficacy of any medications prescribed.
From physiology to pathology
Numerous studies have shown the erectile state of the penis to be dependent upon a balance between contractant and relaxant factors. In a flaccid state, the penis is not at rest, it is in a contractile state due to the predominance of contractant factors tipping the balance.
Most of the peripheral factors mediating relaxation of the penis have been determined including acetylcholine, nitric oxide, vasoactive interstitial peptide and prostanoids. 7 Contractile transmitters and modulators include noradrenaline (NA), endothelin-1, prostanoids and angiotensin II. 7 NA is one of the main modulators of the contractile state. 5 It has been demonstrated that intracavernous injection of a-adrenergic agonists results in maximum contraction 8 while antagonists produce erections. 9 Similar results have been demonstrated ex vivo using isolated smooth muscle cells from human penile corpus cavernosum. 10 The role of NA is not limited to the peripheral nervous system. Autonomic and somatic nuclei in the lumbosacral spinal cord receive inputs from noradrenergic neurones in the brain stem, thus demonstrating a central role for NA. 11 Studies from paraplegic men with higher cord lesions suggest that this higher input is actually inhibitory as touch-based erections are increased in such men. Apomorphine SL therapy P Costa
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The peripheral and central role of NA suggests that high levels of NA would result in a reduced erectile ability. Interestingly, this is supported by studies of psychogenic ED patients who have high levels of NA in penile blood. 13, 14 Additionally, these patients have impaired responses to intracavernosal injections of PGE-1.
15,16
From physiology to management Psychogenic ED patients have peripheral NA alterations and impaired responses to PGE-1 suggest that psychological factors are impacting on the balance of relaxant and contractant factors involved in erectile function. This then leads to the possibility that psychosexual mechanisms can interfere with sexual arousal as has been demonstrated, particularly in the case of anxiety, in numerous studies. [17] [18] [19] This is not merely an esoteric observation but points to effective ED management strategies that could be employed in the primary care setting. When initiating therapy, normalising the orthosympathetic tone could move a patient from a poorresponder group (Figure 2 ) to a high-responder group thus producing a patient with far more likelihood of responding to pharmacotherapy. Normalising this tone requires dealing with anxiety issues, either through anxiolytic therapy or psychosexual counselling.
Conclusions
The pharmacology of apo SL displays a multidimensional nature with an efficacious central mechanism of action, rapid onset of action, and a good tolerability and safety profile that makes it a particularly useful addition to the physicians armamentarium against ED. [1] [2] [3] [4] If pharmacotherapy is integrated into a multidisciplinary approach with effective psychosexual counselling, the efficacy of pharmacotherapy could be improved as we move patients from being at high risk of failure towards a good-responder profile.
High-risk failure profile Good responders Figure 2 From physiology to management: moving the patient from a high-risk failure profile towards a good-responder profile.
Apomorphine SL therapy P Costa S15
